We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Cardiac Imaging Test Targets Developing Countries

By MedImaging International staff writers
Posted on 08 Jun 2017
Print article
Image: Dr. Katia Menacho showing CMR results from the Peruvian study at UCL (Photo courtesy of Cienciactiva).
Image: Dr. Katia Menacho showing CMR results from the Peruvian study at UCL (Photo courtesy of Cienciactiva).
A new cardiovascular magnetic resonance (CMR) imaging test designed for developing countries is three times faster and less than one-fifth the cost of standard CMR, according to a new study.

Researchers at University College London (UCL, United Kingdom), in collaboration with international academic and political representatives from Peru, the United Kingdom, the United States, and Brazil, adapted a current UCL protocol initially developed to assess iron overload in patients with thalassaemia major with the aim of reducing average CMR scan time from 60 minutes to about 15. The original protocol was modified by adding gadolinium as a contrast agent, which is critical for detecting cardiac fibrosis and infarction in the diagnosis of various cardiovascular diseases.

The ultrafast CMR protocol was tested over two days at two hospitals in Peru, accompanied by training for local cardiologists, radiologists, and technicians; the study involved 100 patients with suspected cardiomyopathy and 11 healthy controls. All scans were diagnostic, although two patients underwent a repeat scan, one due to failure of contrast delivery and one to confirm unexpected cardiac amyloidosis. Gadolinium-based contrast agents were administered to 95% of the patients, and there were no scan-related complications.

Each ultrafast CMR scan took 18 minutes on average, and cost USD 150. The most common underlying diagnoses were hypertrophic cardiomyopathy (21%), non-ischemic dilated cardiomyopathy (17%), and ischemic cardiomyopathy (11%), plus 20 other diagnoses including tumors, congenital heart disease (CHD), myocardial iron overload, amyloidosis, vasculitis, and apical thrombus. The CMR had an impact on the clinical management of 33% of patients, and revealed a new, unsuspected diagnosis in 20% of patients, leading to a complete change in management. The study was presented at EuroCMR, held during May 2017 in Prague (Czech Republic).

“Accurate diagnoses provided by CMR have reduced morbidity and mortality in Europe, and we hope to find the same in Peru,” said lead author Peruvian cardiologist Katia Menacho, MD, a PhD student at UCL. “If we show long-term benefits on prognosis we will seek support from the Peruvian government to provide ultrafast CMR at more hospitals in Peru. The accurate diagnosis provided by CMR should lead to more targeted patient care and better outcomes.”

Related Links:
University College London

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Wireless Handheld Ultrasound System
TE Air
Silver Member
Mobile X-Ray Barrier
Lead Acrylic Mobile X-Ray Barriers
New
Ultrasound System
Voluson Signature 18

Print article
Radcal

Channels

MRI

view channel
Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.